Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

被引:65
作者
Meyer, Emmanuel [1 ,2 ]
Pasquier, David [3 ,4 ]
Bernadou, Guillemette [5 ]
Calais, Gilles [5 ]
Maroun, Pierre [6 ]
Bossi, Alberto [6 ]
Theodore, Christine [7 ]
Albiges, Laurence [8 ]
Stefan, Dinu [1 ,2 ]
de Crevoisier, Renaud [9 ]
Hennequin, Christophe [10 ]
Lagrange, Jean-Leon [11 ]
Grellard, Jean-Michel [2 ]
Clarisse, Benedicte [2 ]
Licaj, Idlir [2 ]
Habrand, Jean-Louis [1 ]
Carrie, Christian [12 ]
Joly, Florence [2 ,13 ]
机构
[1] Ctr Francois Baclesse, Dept Radiat Oncol, F-14000 Caen, France
[2] Ctr Francois Baclesse, Dept Clin Res, F-14000 Caen, France
[3] Lille Univ, Ctr Oscar Lambret, Acad Dept Radiat Oncol, F-59000 Lille, France
[4] CNRS, UMR 9189, CRISTAL, Lille, France
[5] Dept Radiat Oncol, Clin Oncol & Radiotherapie, F-37000 Tours, France
[6] Inst Gustave Roussy, Dept Radiat Oncol, F-94800 Villejuif, France
[7] Hop Foch, Dept Clin Oncol, F-92151 Suresnes, France
[8] Gustave Roussy, Dept Clin Oncol, F-94800 Villejuif, France
[9] Ctr Eugene Marquis, Dept Radiat Oncol, F-35000 Rennes, France
[10] Hop St Louis, Dept Radiat Oncol, F-75010 Paris, France
[11] Hop Henri Mondor, Dept Radiat Oncol, F-94010 Creteil, France
[12] Ctr Leon Berard, Dept Radiat Oncol, F-69008 Lyon, France
[13] Ctr Francois Baclesse, Dept Clin Oncol, F-14000 Caen, France
关键词
Renal cell carcinoma; Stereotactic radiation therapy; Oligometastatic disease; Oligoprogressive disease; BODY RADIOTHERAPY; OUTCOMES; SAFETY;
D O I
10.1016/j.ejca.2018.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Renal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the management of metastatic RCC patients. Methods: Data of all RCC patients who received SRT between 2008 and 2015 with curative intent were retrospectively collected in six French referral centres. Local control (LC), progression-free survival (PFS), local recurrence-free survival (LRFS), time to systemic therapy (TTS) and overall survival (OS) were assessed. Results: One hundred and eighty-eight patients treated with SRT for 252 RCC metastases (brain [n = 120]; spine [n = 75]; and others [n = 57]) were recensed. SRT was performed for oligoprogressive disease (101 patients), oligometastatic disease (80 patients) or residual tumour after a partial response to systemic treatment (7 patients). The median biologically effective dose was 78 Gy. For the whole population, local control rates at 6, 12 and 24 months were 87.5%, 82.9% and 77.6%, respectively; median PFS, LRFS, TTS and OS were 8.5, 23.2, 13.2 and 29.2 months, respectively. Among patients treated for oligoprogressive/oligometastatic disease, the median PFS, TTS, and OS were 8.6/7.6, 10.5/14.2 and 23.2/33.9 months, respectively. Among the 7 patients treated with SRT after partial response to systemic treatment, no relapse occurred for 3 of them after a median follow-up of 22 months. Acute and late severe toxicities were noted in 5 (2.6%) patients. Conclusions: SRT is effective and safe for oligometastatic and oligoprogressive RCC patients and may delay introduction or change of systemic therapy. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:38 / 47
页数:10
相关论文
共 30 条
[21]   Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma [J].
Ranck, Mark C. ;
Golden, Daniel W. ;
Corbin, Kimberly S. ;
Hasselle, Michael D. ;
Liauw, Stanley L. ;
Stadler, Walter M. ;
Hahn, Olwen M. ;
Weichselbaum, Ralph R. ;
Salama, Joseph Kamel .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (06) :589-595
[22]   Immune effects of high dose radiation treatment: implications of ionizing radiation on the development of bystander and abscopal effects [J].
Sologuren, Ithaisa ;
Rodriguez-Gallego, Carlos ;
Carlos Lara, Pedro .
TRANSLATIONAL CANCER RESEARCH, 2014, 3 (01) :18-31
[23]   Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma [J].
Staehler, Michael ;
Haseke, Nicolas ;
Nuhn, Philipp ;
Tuellmann, Cordula ;
Karl, Alexander ;
Siebels, Michael ;
Stief, Christian G. ;
Wowra, Berndt ;
Muacevic, Alexander .
BJU INTERNATIONAL, 2011, 108 (05) :673-678
[24]   A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update [J].
Sternberg, Cora N. ;
Hawkins, Robert E. ;
Wagstaff, John ;
Salman, Pamela ;
Mardiak, Jozef ;
Barrios, Carlos H. ;
Zarba, Juan J. ;
Gladkov, Oleg A. ;
Lee, Eunsik ;
Szczylik, Cezary ;
McCann, Lauren ;
Rubin, Stephen D. ;
Chen, Mei ;
Davis, Ian D. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) :1287-1296
[25]   A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma [J].
Svedman, Christer ;
Sandstrom, Per ;
Pisa, Pavel ;
Blomgren, Henric ;
Lax, Ingemar ;
Kalkner, Karl-Mikael ;
Nilsson, Sten ;
Wersall, Peter .
ACTA ONCOLOGICA, 2006, 45 (07) :870-875
[26]   Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases [J].
Wang, Chiachien Jake ;
Christie, Alana ;
Lin, Mu-Han ;
Jung, Matthew ;
Weix, Derek ;
Huelsmann, Lorel ;
Kuhn, Kristin ;
Meyer, Jeffrey ;
Desai, Neil ;
Kim, D. W. Nathan ;
Pedrosa, Ivan ;
Margulis, Vitaly ;
Cadeddu, Jeffrey ;
Sagalowsky, Arthur ;
Gahan, Jeffrey ;
Laine, Aaron ;
Xie, Xian-Jin ;
Choy, Hak ;
Brugarolas, James ;
Timmerman, Robert ;
Hannan, Raquibul .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01) :91-100
[27]   Oligometastases revisited [J].
Weichselbaum, Ralph R. ;
Hellman, Samuel .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (06) :378-382
[28]   Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma [J].
Wersäll, PJ ;
Blomgren, H ;
Lax, I ;
Kälkner, KM ;
Linder, C ;
Lundell, G ;
Nilsson, B ;
Nilsson, S ;
Näslund, I ;
Pisa, P ;
Svedman, C .
RADIOTHERAPY AND ONCOLOGY, 2005, 77 (01) :88-95
[29]   Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors [J].
Yu, Helena A. ;
Sima, Camelia S. ;
Huang, James ;
Solomon, Stephen B. ;
Rimner, Andreas ;
Paik, Paul ;
Pietanza, M. Catherine ;
Azzoli, Christopher G. ;
Rizvi, Naiyer A. ;
Krug, Lee M. ;
Miller, Vincent A. ;
Kris, Mark G. ;
Riely, Gregory J. .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) :346-351
[30]   TUMOR CONTROL OUTCOMES AFTER HYPOFRACTIONATED AND SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES FROM RENAL CELL CARCINOMA [J].
Zelefsky, Michael J. ;
Greco, Carlo ;
Motzer, Robert ;
Magsanoc, Juan Martin ;
Pei, Xin ;
Lovelock, Michael ;
Mechalakos, Jim ;
Zatcky, Joan ;
Fuks, Zvi ;
Yamada, Yoshiya .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05) :1744-1748